ACADIA PHARMACEUTICALS INC — Director's Dealing 2021

Feb 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-02-23

Reporting Person: DAVIS STEPHEN (Director, CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-23	Stock Options (Right to Buy)	$49.74	A	161230	Acquired	2031-02-23	Common Stock (161230)	Direct
2021-02-23	Restricted Stock Units	$	A	43782	Acquired		Common Stock (43782)	Direct

Footnotes

F1: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2022. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

F2: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

F3: The restricted stock units vest in four equal annual installments beginning February 23 2022.